Associations of Serum Levels of Sex Hormones in Follicular and Luteal Phases of the Menstrual Cycle with Breast Tissue Characteristics in Young Women

Linda Linton¹, Monica Taylor¹, Sheila Dunn⁴, Lisa Martin¹, Sonia Chavez², Greg Stanitz², Ella Huszti¹, Salomon Minkin³, Norman Boyd¹*

¹ Campbell Family Institute for Breast Cancer Research, Toronto, ON, Canada, ² Sunnybrook Health Sciences Centre, Toronto, ON, Canada, ³ Princess Margaret Cancer Centre, and Imaging Research, Toronto, ON, Canada, ⁴ Family Practice Health Centre, Women’s College Hospital, Toronto, ON, Canada

* boyd@uhnres.utoronto.ca

Abstract

Background

In previous work in young women aged 15–30 years we measured breast water and fat using MR and obtained blood for hormone assays on the same day in the follicular phase of the menstrual cycle. Only serum growth hormone levels and sex hormone binding globulin (SHBG) were significantly associated with percent breast water after adjustment for covariates. The sex hormones estradiol, progesterone and testosterone were not associated with percent water in the breast in the follicular phase of the menstrual cycle. In the present study we have examined the association of percent breast water with serum levels of sex hormones in both follicular and luteal phase of the menstrual cycle.

Methods

In 315 healthy white Caucasian young women aged 15–30 with regular menstrual cycles who had not used oral contraceptives or other hormones in the previous 6 months, we used MR to determine percent breast water, and obtained blood samples for hormone assays within 10 days of the onset of the most recent menstrual cycle (follicular phase) of the cycle on the same day as the MR scan, and a second blood sample on days 19–24 of the cycle. Serum progesterone levels of > = 5 mmol/L in days 19–24 were used to define the 225 subjects with ovulatory menstrual cycles, whose data are the subject of the analyses shown here.

Results

SHBG was positively associated with percent water in both follicular and luteal phases of the menstrual cycle. Total and free estradiol and total and free testosterone were not associated with percent water in the follicular phase, but in young women with ovulatory cycles, were all negatively associated with percent water in the luteal phase.
Conclusions

Our results from young women aged 15–30 years add to the evidence that the extent of fibroglandular tissue in the breast that is reflected in both mammographic density and breast water is associated positively with higher serum levels of SHBG, but not with higher levels of sex hormones.

Introduction

Mammographic density is a heritable quantitative trait that is a strong risk factor for breast cancer in middle aged and older women[1, 2]. Little is known about the factors that influence this risk factor in early life. To avoid use of radiation we have used magnetic resonance (MR) to measure the water content of the breast, which like mammographic density, reflects fibro-glandular breast tissue [3].

Several established risk factors for breast cancer, including age at menarche, age at first pregnancy, parity, age at menopause, postmenopausal obesity, and use of combined hormone replacement therapy, suggest that variations in exposure to estrogen play a role in the etiology of the disease[4]. Meta-analyses have shown serum levels of estradiol to be associated with risk of breast cancer in both premenopausal [5] and postmenopausal women [6]. Some menstrual and reproductive risk factors for breast cancer, notably parity and menopause and combined hormone therapy, but not estrogen alone, also influence percent mammographic density (PMD) [7, 8]. These data suggest that estrogen, or other sex hormones, may also influence PMD.

In previous work in young women aged 15–30 years we measured breast water and fat using MR and obtained blood for hormone assays on the same day in the follicular phase of the menstrual cycle [9]. Only serum growth hormone (GH) levels and sex hormone binding globulin (SHBG) were significantly and positively associated with percent breast water after adjustment for covariates. The sex hormones estradiol, progesterone and testosterone were not associated with percent water in the breast in the follicular phase of the menstrual cycle.

In the present study we have examined the association of these sex hormones, SHBG and prolactin measured in the luteal phase of the menstrual cycle with percent breast water, and compare the results obtained in follicular and luteal phases. Anovulatory menstrual cycles are common in young women and we have analyzed the results according to the luteal phase defined by the serum progesterone level.

Methods

A. General method

Between 2003 and 2006 we recruited healthy white Caucasian young women aged 15–30, and from 2007 to the present young women aged 15–18. Written informed consent from both subjects and their mothers was required before participation. These procedures were approved by ethics committees of the University Health Network, Sunnybrook Health Sciences Centre, Mount Sinai Hospital, Toronto, The Toronto District School Board and The Toronto District Catholic School Board. We used MR to examine breast tissue and also obtained anthropometric measures and other data that were used to examine factors associated with variations in breast tissue, including blood samples for hormone assays. With the consent of these school boards, and several private schools, we have presented information about the study in Toronto high schools and invited eligible young women to participate. To date a total of 957 young women have participated in the study.
women aged 15–18 and their mothers have given written informed consent to take part in the study.

A subset of 315 of these young women, who had regular menstrual cycles and had not used oral contraceptives or other hormones during the previous 6 months were asked to take part in the present study and provide the measurements and data described below.

B. Measurements

1. MR measures of breast water and fat. The first 181 young women included in the analysis were examined using a 1.5T Signa Cvi MR system (GE, Waukesha WI) using previously described methods [9]. The remaining 44 subjects were examined in a 3.0T scanner (Phillips). All scans were carried out in the prone position with commercially available breast coils from the respective vendors.

To determine if the data from these two scanners could be pooled we scanned 12 healthy volunteers on both scanners on the same day. Total fat and water measures from the two scanners were strongly correlated ($R^2 > 0.99$) and showed some overestimation of fat in the 1.5 T protocol relative to the T3.0 protocol. We therefore applied a correction applied to the T3.0 protocol that decreased the discrepancy [10].

With both scanners the sequence was carefully calibrated for both volume and fat/water percentages using a series of home-built phantoms. A QC program was maintained throughout this study to verify the accuracy and stability of these MR measurements. Bi-monthly scans of three phantoms with known water/oil concentrations and various volumes using the same MR imaging protocol confirmed volume accuracy within 2% and water/oil content accuracy within 3%.

The output of the MR examination was a series of "slices" at 7-mm intervals through both breasts. The breast was distinguished from surrounding tissues on each slice by an observer using a locally-developed, semi-automated image analysis program, and the water and fat within each slice calculated and summed over all slices which acquires the water and fat signals with phase shifts of (0, $\pi$, 2$\pi$). Results shown below are measurements in the right breast only and are expressed as percent water, and in S1–S3 Tables as total breast water and fat. We have shown percent breast water and total water and fat measurements to be bilaterally symmetrical [11].

2. Data collection. We collected data by questionnaire on menstrual, reproductive and familial risk factors, and measured height and weight. We collected venous blood samples in the follicular phase of the menstrual cycle after a 12-hour fast early on the morning of the day of the MR examination, and within 10 days of the onset of the last menstrual period. We collected a second fasting blood collection in the assumed luteal phase, 19–24 days after the onset of the last menstrual period. At each collection, serum was separated within 2 hours, divided into 2 ml aliquots, and stored at –70°C until analysis.

3. Hormone assays. Assays were performed in the Pathology Laboratory of Mount Sinai Hospital Research Services, Toronto, Canada. The methods used, coefficients of variation (CV) and minimum detectable levels (MDL) were as follows. All assays were immunoassays from "ECLIA", Roche Diagnostics. Estradiol: (CV: 9.1%; MDL: 18.4pmol/L); Testosterone: (CV: 4.2%; MDL:0.069 nmol/L (0.02 ng/mL)); Progesterone: (CV: 5.8%; MDL: 0.095nmol/L); SHBG: (CV: 3.5%; MDL: 0.35 nmol/L); Prolactin: (CV: 1.9%; MDL:0.47 ng/ml). Free hormone levels were calculated according to the law of mass action described by Sodergard [12]. Coefficients of variation of <10% were considered acceptable.

In 90 subjects serum progesterone levels in the assumed luteal phase were less than 5 mmol/L and these subjects were excluded from the analysis, which was carried out in the remaining
225 subjects in whom serum progesterone levels indicated that they had ovulated. All hormone levels in the remaining 225 subjects were above the lower level of detection with the exception of eight subjects in whom prolactin was below the lower detection limit. Prolactin secretion by the pituitary is known to be episodic and these subjects were retained in the analysis.

C. Statistical methods

Means and standard deviations were calculated for selected characteristics, and median values and interquartile ranges for hormone measurements. Hormone measurements in the follicular and luteal phase were compared using a two-sided Wilcoxon signed-rank test. Total water and total fat were log transformed for analysis.

The associations of MR breast tissue characteristics with hormone levels were examined using both univariable and multivariable regression models. The latter models included age, and age at menarche, anthropomorphic measures, and number of days since the most recent menstrual period (LMP).

To illustrate the main findings of regression analysis, we ran multivariable regression analyses with selected hormones divided into quintiles. The statistical significance of the differences in breast measures of percent water with increasing levels of these variables were assessed using tests for linear, and, when appropriate, for quadratic trend. A statistical test for quadratic trend was used when, on inspection of the quintile plots shown in Figs 1–3, the association of percent water with serum levels of a hormone was non-linear (e.g. see Fig 2 for free estradiol in subjects aged 15–18 years).

The analyses were conducted using R 2.15.1 statistical software. All p-values were calculated from two-tailed tests of statistical significance. Statistical significance was declared at 5% level. All p-values shown are adjusted for the variables shown in the table footnote.

Results

a. Characteristics of subjects

Table 1 shows selected characteristics of the 225 subjects with ovulatory menstrual cycles. Their mean age at the time of the MR scan was 19.9 years (standard deviation (SD) was 4.7 years). The mean age at menarche was 12.3 years (SD 1.1 years). Twenty three percent had previously used oral contraceptives (OCs), and all had stopped OCs at least 6 months before participating in the present study. The mean interval between the onset of the most recent menstrual period (LMP) and the date of the MR scan and follicular phase blood collection was 8 days (SD: 2.5 days). The luteal blood collection was on average 22.3 days after the onset of the LMP (SD: 4.0 days).

b. Serum hormones in follicular and luteal phases of menstrual cycle

Table 2 shows serum levels of the measured hormones in all 225 subjects according to the follicular and luteal phases of the menstrual cycle. Serum levels of sex hormone binding globulin (SHBG), estradiol (total and free), and progesterone were each significantly higher in the luteal than in the follicular phase of the menstrual cycle (all p<0.0001). Testosterone (total and free) and prolactin were significantly lower in the luteal than in the follicular phase of the cycle (both p<0.0001).

Similar results were seen when the analysis was restricted to the 187 subjects in whom follicular and luteal phase blood samples were obtained in the same menstrual cycle (shown in S1 Table).
c. Percent breast water and serum hormone levels

Table 3 shows the regression coefficients and p-values that describe the association of each hormone with percent water in the breast, after adjustment for the variables shown in the footnote to Table 3.

Serum levels of SHBG were positively associated with percent water in both follicular and luteal phases (both \( p < 0.0001 \)). In both follicular and luteal phases of the cycle serum levels of total estradiol were not significantly associated with percent water (respectively \( p = 0.20 \) and \( p = 0.61 \) for total estradiol). Free estradiol was not significantly associated with percent water in the follicular phase (\( p = 0.82 \)) but was inversely associated with percent water in the luteal phase (\( p = 0.01 \)). Serum levels of progesterone were not significantly associated with percent breast water in either phase of the menstrual cycle (respectively \( p = 0.56 \) and \( p = 0.25 \) in follicular and luteal phases). Prolactin was not associated with percent water in either follicular or luteal phase (respectively \( p = 0.90 \) and 0.63).

Figs 1–3 show the directions and magnitudes, according to age, of those hormones that were significantly associated with percent water in Table 3.

Fig 1 shows the association of quintiles of SHBG with percent water according to age and the phase of the menstrual cycle. Statistically significant positive associations between SHBG and percent breast water were seen in follicular and luteal phases of the cycle in young women aged 15–18 years, but were weaker and significant only in the luteal phase for young women aged 18–30 years.

Fig 2 shows that the inverse association of free estradiol with percent water was statistically significant in all subjects, but an inverse linear association was significant only in 18–30 year old subjects (\( p = 0.03 \)). In the follicular phase in 18–30 year old subjects a statistically significant quadratic association was seen (\( p = 0.03 \)).

As shown in Fig 3, free testosterone was inversely associated with percent water in both follicular and luteal phases, but this inverse association was statistically significant only in the luteal phase in 15-18 year old subjects.

d. Total breast water and fat and serum hormone levels

The association of SHBG and free testosterone with percent water are likely to be the result of associations between these variables and total water or fat in the breast, measures from which the ratio percent water is calculated. Results of these analyses are shown in S2 and S3 Tables.

SHBG was significantly and inversely associated in both menstrual phases with the total fat volume of the breast (both \( p = 0.01 \)), but was not significantly associated with total water in either phase (respectively \( p = 0.12 \) and 0.13). Free testosterone was not significantly associated with either total water or fat in the breast, but had an inverse association, of borderline significance (\( p = 0.10 \)) with total water in the follicular phase and a weak positive association with total fat (\( p = 0.18 \)) in the luteal phase.

Discussion

Mammographic density in mid-life has been shown to be a strong, heritable risk factor for breast cancer [1, 2], that may be in part the combined result of genetic influences and growth and development in early life that determine breast tissue composition in adolescence [9].
Breast water has been shown to reflect fibroglandular tissue in the breast, as does mammographic density, and percent breast water and percent mammographic density are strongly correlated [13].

The present results show that in young women aged 15–30 years, after adjustment for weight, serum levels of SHGB were significantly and positively associated with percent water in the breast in both follicular and luteal phases of the menstrual cycle. A similar association of SHBG with breast tissue characteristics has been found previously in young women [9, 14], and in adult premenopausal and postmenopausal women by some [15, 16] but not all [17–20] investigators.

Although some previous studies have not identified any consistent change in serum levels of SHBG over the menstrual cycle, several studies have now reported higher levels of SHBG in the luteal phase compared to the follicular phase of the menstrual cycle, similar to the differences seen in the present study. These include studies in normal adult females [21, 22] [23] and in girls in puberty and adolescence [24] in whom SHBG levels were higher in the luteal than the follicular phase only in those with ovulatory cycles.

In the present study, total and free estradiol and testosterone were not significantly associated with percent water in the follicular phase of the menstrual cycle but in the luteal phase both total and free estradiol and testosterone were each significantly inversely associated with percent water.

SHBG transports estrogens and androgens in the blood and regulates access of these hormones to reproductive tissues whose growth and development they control (reviewed in [25]). In addition to the role of SHBG in hormone transport, it is known to be associated with several metabolic variables whose association with PMD has not yet been fully examined. For example, higher concentrations of SHBG have been associated with a lower risk cardio-metabolic profile, less adiposity and greater insulin sensitivity [26]. In female twin and sister studies it has been estimated that 56% of the variance (heritability) in serum levels of SHBG is explained by inherited variants [27, 28] and genetic variants associated with differences in mean serum levels of SHBG have been identified [29, 30]. It therefore appears likely that the association of SHBG with BD is not solely a reflection of BMI or weight, but may be related to the mechanism(s) underlying BD.

Strengths of the present study include the measurement of breast water by MR, which is quantitative, volumetric and requires little input from an observer, the standardized collection and handling of blood, and the collection of information on a wide range of potential confounding variables. Further, blood for hormone assays was collected and handled in a standardized manner at carefully defined times in the menstrual cycle.

A potential limitation of the study is that, for logistical reasons, MR scans were performed only in the follicular phase of the cycle. However, Graham et al showed little or no variation in breast water measured in repeated MR scans throughout the menstrual cycle in adult premenopausal women [31].

Our results add to the evidence that the extent of fibroglandular tissue in the breast that is reflected in both mammographic density and breast water is not associated with higher serum levels of sex hormones in either the follicular or luteal phases of the menstrual cycle. Few studies of blood levels of ovarian hormones and PMD in premenopausal women have been published to date and none have found an association [32–35],[36, 37]
Fig 3. Free testosterone at follicular or luteal phase with MRI measurements in young women. Young women with progesterone levels less than 5 in the luteal phase were excluded. Model adjusted for Age at MRI; Age at Menarche; Weight; Height and Days since LMP for each phase. P: test for linear trend

doi:10.1371/journal.pone.0163865.g003
Further, circulating sex steroid levels and mammographic density have been found to be strongly and independently associated with the risk of breast cancer in postmenopausal women in 2 distinct populations. While both mammographic density and serum levels of sex hormones show evidence of heritability, there is no evidence of overlap between them [38] and no evidence of a shared genetic basis between any sex hormone and any mammographic measure. However, percent mammographic density (PMD) has been shown to increase after use of combined hormone therapy, although not with estrogen alone [7], and to be reduced by Tamoxifen [39].

A separate larger study now in progress will examine the association of genetic variants with breast tissue characteristics and serum levels of hormones in young women.

### Table 1. Selected characteristics of subjects with ovulatory menstrual cycles.

| Risk Factors | N = 225 |
|--------------|---------|
| Age at time of MRI | 19.9 (4.7) |
| Weight (kg) | 59.5 (9.5) |
| Height (cm) | 165.6 (5.5) |
| Body mass index (kg/m²) | 21.6 (3.1) |
| Age at menarche (years) | 12.3 (1.1) |
| Days since LMP–Follicular | 8.0 (2.5) |
| Days since LMP–Luteal | 22.3 (4.0) |
| Consumed alcohol at least once per week for 6 months or more (%) | 29.0% |
| Smoked at least once per week for 6 months or more (% yes) | 15.6% |
| First degree relative with cancer (% yes) | 7.6% |
| Past use of oral contraceptives (% yes) | 22.8% |

### MRI measurements

- Percent water (%) | 50.9 (22.2)
- Total water (cm³) | 230.3 (120.2)
- Total fat (cm³) | 232.5 (240.3)
- Total volume (cm³) | 502.8 (313.9)

- Continuous risk factors are expressed as mean (SD), binary risk factors expressed as % yes.
- N = 224.
- MRI measurements are expressed as median (IQR).

### Table 2. Hormone measurements in subjects with ovulatory menstrual cycles.

| Hormones | Follicular (N = 225) | Luteal (N = 225) |
|----------|----------------------|-----------------|
| SHBG (nmol/L) | 54.5 (27.4) | 62.7 (35.5) |
| Estradiol (pmol/L) | 187.0 (143.0) | 434.0 (259.0) |
| Free Estradiol (pmol/L) | 2.7 (1.8) | 5.8 (3.2) |
| Progesterone (nmol/L) | 2.0 (1.0) | 23.0 (29.0) |
| Testosterone (nmol/L) | 1.7 (1.1) | 0.9 (0.7) |
| Free Testosterone (nmol/L) | 0.015 (0.011) | 0.008 (0.006) |
| Prolactin (ng/L) | 22.0 (17.0) | 16.0 (11.0) |

- Hormone measurements are expressed as median (IQR); test of significance of the difference between hormones in the follicular phase versus luteal phase was performed using a Wilcoxon signed-rank test, two-sided.
- N = 217.

References

[38] Further, circulating sex steroid levels and mammographic density have been found to be strongly and independently associated with the risk of breast cancer in postmenopausal women in 2 distinct populations. While both mammographic density and serum levels of sex hormones show evidence of heritability, there is no evidence of overlap between them and no evidence of a shared genetic basis between any sex hormone and any mammographic measure. However, percent mammographic density (PMD) has been shown to increase after use of combined hormone therapy, although not with estrogen alone, and to be reduced by Tamoxifen.

[39] A separate larger study now in progress will examine the association of genetic variants with breast tissue characteristics and serum levels of hormones in young women.
Supporting Information

S1 Table. Hormone measurements in follicular and luteal phases of the same menstrual cycle.

| Hormones                  | FOLLICULAR PHASE | LUTEAL PHASE |
|---------------------------|------------------|--------------|
|                           | Adjusted Regression Coefficient | P-value | Adjusted Regression Coefficient | P-value |
| SHBG (nmol/L)             | 7.90             | <0.0001      | 8.16             | <0.0001 |
| Estradiol (pmol/L)        | 2.03             | 0.20         | -0.99            | 0.61    |
| Free Estradiol (pmol/L)   | -0.37            | 0.82         | -4.87            | 0.011   |
| Progesterone (nmol/L)     | 0.99             | 0.56         | 1.27             | 0.25    |
| Testosterone (nmol/L)     | 0.22             | 0.80         | -1.03            | 0.55    |
| FreeTestosterone (nmol/L) | -3.00            | 0.03         | -3.12            | 0.02    |
| Prolactin* (ng/L)         | -0.19            | 0.90         | -0.74            | 0.63    |

Young women with ovulatory menstrual cycles were used in the analysis (N = 224 in the multivariable models). All data were analyzed as continuous variables after log transformation (except testosterone). Estimated regression coefficients and corresponding p-values are shown after adjustment for covariates. Covariates were age at MRI (years), age at menarche (years), weight (kg), height (cm) and days since LMP for each phase. All hormone variables except testosterone were log transformed.

* N = 217 (N = 216 for the multivariable model) in Follicular Phase.

doi:10.1371/journal.pone.0163865.t003

Acknowledgments

We acknowledge the assistance with recruitment of subjects provided by Angela Tang, Monica Dela Cruz, Maria Ramirez, Rachel Roke, Jessica Russell, Sharine Ahmed, and Danielle Pagnan.

Author Contributions

Conceptualization: NFB SM LM LL MT.
Data curation: LL MT.
Formal analysis: EH JZ SM LH NFB.
Funding acquisition: NFB LM SM.
Methodology: LL MT SC GS.
Project administration: LL MT NFB.
Resources: SD LL MT.
Software: SG GS.
Writing – original draft: NFB.
Writing – review & editing: LL LM SH SD GS SC.

References

1. McCormack VA, dos Santos Silva I: Breast density and parenchymal patterns as markers of breast cancer risk: A meta-analysis. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2006, 15(6):1159–1169. doi: 10.1158/1055-9965.EPI-06-0034 PMID: 16775176

2. Boyd NF, Dite GS, Stone J, Gunasekara A, English DR, McCredie MRE, Giles GG, Tritchler D, Chiarelli A, Yaffe MJ et al: Heritability of mammographic density, a risk factor for breast cancer. The New England journal of medicine 2002, 347(12):886–894. doi: 10.1056/NEJMoa013390 PMID: 12239257

3. Graham SJ, Ness S, Hamilton BS, Bronskill MJ: Magnetic resonance properties of ex vivo breast tissue at 1.5 T. Magn Reson Med 1997, 38(4):669–677. doi: 10.1002/mrm.1910380422 PMID: 9324335

4. Key TJ, Verkasalo PK, Banks E: Epidemiology of breast cancer. The lancet oncology 2001, 2(3):133–140. doi: 10.1016/S1470-2045(00)00254-0 PMID: 11902563

5. Endogenous H, Breast Cancer Collaborative G, Key TJ, Appleby PN, Reeves GK, Reeves GK, Roddam AW, Helzlsouer KJ, Alberg AJ, Rollison DE, Dorgan JF et al: Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. British journal of cancer 2011, 105(5):709–722. doi: 10.1038/bjc.2011.254 PMID: 21772329

6. Greendale GA, Reboussin BA, Sie A, Singh HR, Olson LK, Gatewood O, Bassett LW, Wasilauskas C, Bush T, Barrett-Connor E: Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Ann Intern Med 1999, 130(4 Pt 1):262–269. doi: 10.7326/0003-4819-130-4_part_1-199902160-00003 PMID: 10068383

7. Yaghjian L, Colditz GA, Rosner B, Bertrand KA, Tamimi RM: Reproductive factors related to childbearing and mammographic breast density. Breast cancer research and treatment 2016, 158(2):351–359. doi: 10.1007/s10549-016-3884-y PMID: 27351801

8. Boyd NF, Martin LJ, Chavez S, Gunasekara A, Salleh A, Melnichouk O, Yaffe M, Friedenreich CM, Minkin S, Bronskill MJ: Breast-tissue composition and other risk factors for breast cancer in young women: a cross-sectional study. The lancet oncology 2009, 10(6):569–580. doi: 10.1016/S1470-2045(09)70078-6 PMID: 19409844

9. Chavez S, Stanisz G: Comparing average breast fat content results from two different protocols at 1.5T and 3T: can the data be pooled? J Magn Reson Imaging 2014, 40(4):890–898. doi: 10.1002/jmri.24452 PMID: 24989130

10. Hennessey S, Huszti E, Gunasekura A, Salleh A, Martin L, Minkin S, Chavez S, Boyd NF: Bilateral symmetry of breast tissue composition by magnetic resonance in young women and adults. Cancer Causes Control 2014, 25(4):491–497. doi: 10.1007/s10552-014-0351-0 PMID: 24477331

11. Sodergard R, Backstrom T, Shanbhag V, Carstensen H: Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. J Steroid Biochem 1982, 16(6):801–810. doi: 10.1016/0022-4731(82)90038-3 PMID: 7202083

12. Poorn CS, Bronskill MJ, Henkelman M, Boyd NF: Quantitative magnetic resonance imaging parameters and their relationship to mammographic pattern. Journal of the National Cancer Institute 1992, 84(10):777–780. doi: 10.1093/jnci/84.10.777 PMID: 1573664

13. Jung S, Egleston BL, Chandler DW, Van Horn L, Hytton NM, Kifla CC, Lasser NL, LeBlanc ES, Paris K, Shepherd JA et al: Adolescent endogenous sex hormones and breast density in early adulthood. Breast cancer research: BCR 2015, 17:77. doi: 10.1186/s13058-015-0581-4 PMID: 26041651

14. Tamimi RM, Hankinson SE, Colditz GA, Byrne C: Endogenous sex hormone levels and mammographic density among postmenopausal women. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2005, 14(11 Pt 1):2641–2647. doi: 10.1158/1055-9965.EPI-05-0558 PMID: 16284390
18. Warren R, Skinner J, Sala E, Denton E, Dowsett M, Folkerd E, Healey CS, Dunning A, Doody D, Ponder B et al: Associations among mammographic density, circulating sex hormones, and polymorphisms in sex hormone metabolism genes in postmenopausal women. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2006, 15(8):1502–1508. doi: 10.1158/1055-9965.EPI-05-0828 PMID: 16896040

19. Verheus M, Peeters PH, van Noord PA, van der Schouw YT, Grobbee DE, van Gils CH: No relationship between circulating levels of sex steroids and mammographic breast density: the Prospect-EPIC cohort. Breast cancer research: BCR 2007, 9(4):R53. doi: 10.1186/bcr1758 PMID: 17692133

20. Sprague BL, Trentham-Dietz A, Gangnon RE, Buist DS, Burnside ES, Bowles EJ, Stanczyk FZ, Sisney GS: Circulating sex hormones and mammographic breast density among postmenopausal women. Horm Cancer 2011, 2(1):62–72. doi: 10.1077/s12672-010-0056-0 PMID: 21318123

21. Plymate SR, Moore DE, Cheng CY, Bardin CW, Southworth MB, Levinski MJ: Sex hormone-binding globulin changes during the menstrual cycle. The Journal of clinical endocrinology and metabolism 1985, 61(5):993–996. doi: 10.1210/jcem-61-5-995 PMID: 2413065

22. Dowsett M, Attree SL, Virdée SS, Jeffcoate SL: Oestrogen-related changes in sex hormone binding globulin levels during normal and gonadotrophin-stimulated menstrual cycles. Clin Endocrinol (Oxf) 1985, 23(3):303–312. doi: 10.1111/j.1365-2265.1985.tb00228.x PMID: 4075539

23. Schijf CP, van der Mooren MJ, Doebsg WH, Thomas CM, Rolland R: Differences in serum lipids, lipoproteins, sex hormone binding globulin and testosterone between the follicular and the luteal phase of the menstrual cycle. Acta Endocrinol (Copenh) 1993, 129(2):130–133. doi: 10.1530/acta.0.1290130 PMID: 8372597

24. Apter D, Bolton NJ, Hammond GL, Vihko R: Serum sex hormone-binding globulin during puberty in girls and in different types of adolescent menstrual cycles. Acta Endocrinol (Copenh) 1984, 107(3):413–419. doi: 10.1530/acta.0.1070413 PMID: 6931059

25. Hammond GL: Diverse roles for sex hormone-binding globulin in reproduction. Biol Reprod 2011, 85(3):431–441. doi: 10.1095/biolreprod.111.092593 PMID: 21613632

26. Sorensen K, Akslaaade L, Munch-Andersen T, Aachmann-Andersen NJ, Petersen JH, Hilsted L, Helge JW, Juul A: Sex hormone-binding globulin levels predict insulin sensitivity, disposition index, and cardiovascular risk during puberty. Diabetes Care 2008, 32(9):909–914. doi: 10.2337/dc08-1618 PMID: 19168890

27. Edmunds SE, Stubbs AP, Santos AA, Wilkinson ML: Estrogen and androgen regulation of sex hormone-binding globulin secretion by a human liver cell line. J Steroid Biochem Mol Biol 1990, 37(5):733–739. doi: 10.1016/0960-0760(90)90358-r PMID: 2278857

28. Stone J, Folkerd E, Doody D, Schroen C, Treloar SA, Giles GG, Pike MC, English DR, Southey MC, Ahn MJ, Humphrey NJ, Pollard E et al: Familial correlations in postmenopausal serum concentrations of sex steroid hormones and other metabolites: a twins and sisters study. J Clin Endocrinol Metab 2009, 94(12):4793–4800. doi: 10.1210/jc.2009-0713 PMID: 19850695

29. Covciello AD, Haring R, Wellons M, Vaidya D, Lehtimaki T, Keildson S, Lunetta KL, He C, Fornage M, Lagou V et al: A genome-wide association meta-analysis of circulating sex hormone-binding globulin and other metabolites: a twins and sisters study. J Clin Endocrinol Metab 2009, 94(12):4793–4800. doi: 10.1210/jc.2009-0713 PMID: 19850695

30. Thompson DJ, Healey CS, Baynes C, Kalmyrzaev B, Ahmed S, Dowsett M, Folkerd E, Luben RN, Cox D, Ballinger D et al: Identification of common variants in the SHBG gene affecting sex hormone-binding globulin levels and breast cancer risk in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2008, 17(12):3490–3498. doi: 10.1158/1055-9965.EPI-08-0734 PMID: 19064566

31. Graham SJ, Stanchan PL, Lloyd-Smith JO, Bronskill MJ, Pelews DB: Changes in fibroglandular volume and water content of breast tissue during the menstrual cycle observed by MR imaging at 1.5 T. J Magn Reson Imaging 1995, 5(6):695–701. doi: 10.1002/jmri.1880050613 PMID: 8748488

32. Noh JJ, Maskarin ec G, Pagano I, Cheung LW, Stanczyk FZ: Mammographic densities and circulating hormones: A cross-sectional study in premenopausal women. Breast 2006, 15(1):20–28. doi: 10.1016/j.breast.2005.04.014 PMID: 16000251

33. Aiello EJ, Buist DSM, White E, Porter PL: Association between mammographic breast density and breast cancer tumor characteristics. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2005, 14(3):662–668. doi: 10.1158/1055-9965.EPI-04-0327 PMID: 15767347

34. Warren R, Skinner J, Sala E, Denton E, Dowsett M, Folkerd E, Healey CS, Dunning A, Doody D, Ponder B et al: Associations among mammographic density, circulating sex hormones, and polymorphisms in sex hormone metabolism genes in postmenopausal women. Cancer Epidemiol Biomarkers & Prev 2006, 15(8):1502–1508. doi: 10.1158/1055-9965.EPI-05-0828 PMID: 16896040
35. Boyd NF, Stone J, Martin LJ, Jong R, Fishell E, Yaffe M, Hammond G, Minkin S: The association of breast mitogens with mammographic densities. Br J Cancer 2002, 87(8):876–882. doi: 10.1038/sj.bjc.6600537 PMID: 12373602

36. Iversen A, Frydenberg H, Furberg AS, Flote VG, Finstad SE, McTiernan A, Ursin G, Wilsaard T, Ellison PT, Jasienska G et al: Cyclic endogenous estrogen and progesterone vary by mammographic density phenotypes in premenopausal women. Eur J Cancer Prev 2016, 25(1):9–18. doi: 10.1097/CEJ.0000000000000130 PMID: 25714648

37. Yong M, Atkinson C, Newton KM, Aiello Bowles EJ, Stanczyk FZ, Westerling KC, Holt VL, Schwartz SM, Leisenring WM, Lampe JW: Associations between endogenous sex hormone levels and mammographic and bone densities in premenopausal women. Cancer causes & control: CCC 2009, 20(7):1039–1053. doi: 10.1007/s10552-009-9321-3 PMID: 19280356

38. Varghese JS, Thompson DJ, Michaillidou K, Lindstrom S, Turnbull C, Brown J, Leyland J, Warren RM, Luben RN, Loos RJ et al: Mammographic breast density and breast cancer: evidence of a shared genetic basis. Cancer Res 2012, 72(6):1478–1484. doi: 10.1158/0008-5472.CAN-11-3295 PMID: 22266113

39. Cuzick J, Warwick J, Pinney E, Cawthorn S, Howell A, Forbes JF, Warren RML: Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study. Journal of the National Cancer Institute 2011, 103(9):744–752. doi: 10.1093/jnci/djr079 PMID: 21483019